Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 6Thoracic 4Lymphoid 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Lymphoma, B-Cell 2

Interventions

Cyclophosphamide 172Rituximab 157Specimen Handling 116Biopsy 93Magnetic Resonance Spectroscopy 90Vincristine 89Doxorubicin 83Prednisone 81fludarabine 70venetoclax 67obinutuzumab 62ibrutinib 55Lenalidomide 55Dexamethasone 55Cytarabine 49Methotrexate 46acalabrutinib 43Etoposide 41blinatumomab 40CT-P10 39Bendamustine Hydrochloride 37fludarabine phosphate 33Gemcitabine 33prednylidene 32Calcium Dobesilate 32deltacortene 31zanubrutinib 30pembrolizumab 29glofitamab 28Nivolumab 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
ALT-803 × Lymphoid × 90 days × Clear all
NCT07049432 2026-04-01

CARMEN-803

University of Utah

Phase 1 Withdrawn
Lymphoid

Lymphoma, B-Cell

NCT07477366 2026-03-17

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

ImmunityBio, Inc.

Phase 2 Not yet recruiting
20 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡